CDC Recommends MenB Vaccination in Late Adolescence — Physician’s First Watch

Medical News |
October 23, 2015

CDC Recommends MenB Vaccination in Late Adolescence

By Cara Adler

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

The recent Advisory Committee on Immunization Practices (ACIP) recommendations on vaccination against serogroup B meningococcal (MenB) disease have been published in MMWR and, thus, are officially endorsed by the CDC.

The key points: Patients ages 16 to 23 may be vaccinated, with a preference for vaccination at ages 16 to 18; ACIP found insufficient evidence to recommend vaccinating all adolescents.

In the past year, the FDA granted accelerated approval to two MenB vaccines (Trumenba and Bexsero), in response to outbreaks of MenB disease at colleges. The vaccines are approved for patients aged 10 to 25 years. ACIP's preference for vaccination at age 16 to 18 is intended to "maximize the likelihood that protection would last into the highest age-related risk period."

Among ACIP's other recommendations for MenB vaccination:

  • The same vaccine should be used for all doses in the series (three doses for Trumenba, two for Bexsero).

  • MenB vaccine can be administered at the same time as other vaccines recommended for this age group, preferably at a different site.

  • Pregnant and lactating women should not be vaccinated unless they are at high risk.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.